Menu
Recruiting NCT07122895

Sex Differences in NMDA-enhancing Treatment of Schizophrenia

Phase II Interventional Schizophrenia

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: NMDAE, Placebo Cap.
Who it may be relevant to
Registry conditions: Schizophrenia. Basic parameters: 20 years — 65 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Taiwan
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Overview

Schizophrenia differs between sexes in clinical symptoms and functional outcome. Negative symptoms are the core pathology of this disease. NMDA receptor (NMDAR) dysfunction is a key factor in negative symptoms. This study aims to examine the sex difference in the efficacy of an NMDA-enhancer (NMDAE) for the treatment of negative symptoms in schizophrenia.

Detailed description

Schizophrenia differs between sexes in clinical symptoms and functional outcome. Negative symptoms, the core pathology of this disease, principally determine the patients' prognoses. NMDAR dysfunction is a key factor in negative symptoms. Whether NMDAR-enhancing treatment can improve negative symptoms and whether there is sex difference need to be studied. The subjects are the schizophrenia patients with predominantly negative symptoms. They will continue their original treatment and be double-blindly, randomly assigned to receive 12-week: (1) NMDAE (N = 60), or (2) placebo (N = 30). There will be half men and half women in each group. We will measure clinical manifestations and side effects at weeks 0, 4, 8, and 12 using Scale for Assessment of Negative Symptoms (the primary outcome), Positive and Negative Syndrome Scale-negative subscale, Clinical Global Impression, Quality of Life Scale, Global Assessment of Function, and scale of side effects. At week 0 and week 12, we will assess 7 cognitive domains. Chi-square (or Fisher's exact test) will be used to compare differences of categorical variables and t-test (or Mann-Whitney test if the distribution is not normal) for continuous variables between treatment groups. Mean changes from baseline in repeated-measure assessments will be assessed using the generalized estimating equation (GEE). All p values for clinical measures will be based on two-tailed tests with a significance level of 0.05.

Interventions

  • Drug NMDAE
    Use of an NMDA enhancer for the treatment of negative symptoms
  • Drug Placebo Cap
    Use of placebo as a comparator

Primary outcome measures

  • Change of scales for the Assessment of Negative Symptoms (SANS) total score [Time frame: week 0, 4, 8, 12]
Secondary outcome measures (5)
  • Change of Negative subscale of PANSS [Time frame: week 0, 4, 8, 12]
  • Change of Clinical Global Impression [Time frame: Frame: week 0, 4, 8, 12]
  • Change of Global Assessment of Functioning composite [Time frame: week 0, 4, 8, 12]
  • Change of Quality of Life Scale [Time frame: week 0, 4, 8, 12]
  • Change of cognitive function composite [Time frame: Week 0, 12]

Eligibility criteria

Inclusion criteria

  • Have a Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) diagnosis of schizophrenia
  • keep stable mentally for ≥ 6 months before baseline and meet the following clinical criteria: predominantly negative symptoms for ≥ 6 months, a minimum baseline total score of 40 on the SANS, a minimum baseline score of 24 on the negative subscale of the PANSS, and a maximum score of 3 on each item of PANSS-positive subscale;
  • Are physically healthy and laboratory assessments (including blood routine, biochemical tests) are clinically insignificant;
  • Have been keeping a fixed dose of antipsychotics for at least 6 months, and that is not allowed to change during the 12-week study period
  • Have sufficient education to communicate effectively and are capable of completing the assessments of the study
  • Agree to participate in the study and provide written informed consent

Exclusion criteria

  • DSM-5 diagnosis of intellectual disability or substance (including alcohol) use disorder
  • History of epilepsy, head trauma, or serious medical or central nervous system diseases (other than schizophrenia) which may interfere with the study
  • Clinically evident depressive symptoms or a baseline score>7 on the Hamilton Depression Rating Scale-17 items
  • Clinically relevant parkinsonism or a baseline score >3 on the sum of the first eight items of the Simpson-Angus Scale (SAS)
  • Pregnancy or lactation
  • Inability to follow protocol

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Triple blind
Primary purpose
Treatment

Study locations

Taiwan · 1 center
  • Department of Psychiatry, China Medical University Hospital — Taichung

Identifiers

NCT: NCT07122895 · CMUH114-REC3-042

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗